ABSTRACT
INTRODUCTION
Hepatitis C virus (HCV) belongs to Flaviviridae family, and its genome is a single-stranded RNA molecule 2 . Chronic hepatitis c virus infection is a major cause of liver disease with worldwide prevalence estimated at 3%. There were 170 million HCV patient worldwide, with 3-4 million new cases appearing each year 20 . About 70-80 % of patients become chronic carriers who may progress to cirrhosis and hepatocellular carcinoma 17, 18 . HCV infection affects more than 4 million people in the united states where it represent the leading cause for liver transplantatio 20 . The most effective Current standard of care therapy in patients with CHC, a combination of PEG-INF-alpha with ribavirin 5 . The SVR rate for individuals infected with genotype 1 CHC, the most common type in developed countries, is the lowest and requires 12 months of therapy. In those infected with other genotypes, SVRs of 75% can be achieved following 6 months of therapy
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.
Occult HCV infection (OCI) means detectable HCV-RNA in the liver or peripheral blood mononuclear cells in the absence of serum HCV-RNA and, or anti-HCV antibodies 10 . Two forms of OCI, secondary OCI in which infection has been found to persist in the presence of antibodies for HCV and normal levels of liver enzymes for years after spontaneous or antiviral therapy-induced resolution of hepatitis C infection. The other form of OCI accompanied by persistently moderately elevated liver enzymes in the absence of antibodies to HCV, which can be termed as cryptogenic OCI
16
. Patient who participates in chronic hemodialysis units are at increased risk for hepatitis C. The prevalence of HCV antibodies in such patients reaches 15%, although it has declined in recent years
7
. The prevalence of occult HCV infection is high among hemodialysis patients with persistently abnormal values of liver enzymes of unknown cause 10 . It was reported that up to 57% of patients with normal renal function but with abnormal liver enzymes of unknown cause have an occult HCV infection detected by presence of HCV-RNA in liver cells. Furthermore, 70% of these patients also have HCV-RNA in the peripheral blood mononuclear cells (PBMC) 3 . In patients chronically infected with HCV, the production of inappropriate amounts of cytokines, such as IL-10, were reported to be associated with HCV clearance, fibrogenesis, and even resistance to interferon therapy 8, 18 . Interleukin 10 is a critical immunoregulatory molecule. It is a member of an expanding family consisting of cellular and viral cytokines
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. IL10, produced mainly by macrophage, Thelper 2 (Th2) cells, and regulatory T cells, is a potent immunosuppressive cytokine as it inhibits the secretion of pro-inflammatory and antiviral cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) 11, 15 . A number of studies have examined the IL10 and their associations with HCV susceptibility as well as resistance to antiviral therapy 13 . High serum levels of IL-10 have been correlated with poor response to interferon therapy, whereas IL-10 production has been found to be lower in responders than in non-responders
4
. The aim of this work is to estimate the serum level of IL10 in hemodialysis patients with abnormal levels of liver enzymes of unknown origin, and comparing these results in population with normal levels of liver enzymes.
METHODOLOGY 1) Patients:
This study was conducted on 75 chronic renal dialysis patients who were repeatedly anti-HCV Abs negative and had abnormal elevated liver enzymes of unknown cause and 10 healthy volunteers who had normal liver enzymes and kidney functions as a control.
Patients were selected from renal dialysis unit of nephrology department, faculty of medicine, Assiut university in the period from October 2012 to June 2014 after informed personal consent. Patient's criteria: A-Inclusion criteria: The inclusion criteria include elevated liver enzymes (ALT&AST), anti-HCV Abs negative, HBsAg negative.
B-Exclusion criteria: Infection with HCV, infection
with HBV, autoimmune hepatitis, drug toxicity, biliary obstruction, active schistosomiasis or malignancies.
2) Samples
3 ml venous blood for separation of peripheral blood mononuclear cells, were collected from all patients and control individuals in an EDTAcontaining sterile tube under complete aseptic condition. PBMCs were obtained by FicollHypaque (FH) density gradient centrifugation of sample according to the manufacturer's instructions.
(Lympholot, Biotest, 63303Dreleich, Germany). 3 ml of venous blood were withdrawn and left for 15 minutes to be clotted and then centrifuged at 3000 rpm for 5 minutes. The serum then used in serological tests including ELISA and biochemical tests. 
RESULTS
The study subjects were classified into group A (patients on renal dialysis with increased liver enzymes NO. = 75) and group B (control persons, NO. = 10).
As regard gender, in the group A, 36 (48%) were male and 39 (52%) were female. While in the group B the number of males were 6 (60%) and that of females were 4 (40%).
The range and mean of age among the studied sample. In group A, the range was between 18 to 70 year (mean +SD: 47.3+11.7 year), while the range of group B was between 22 to 50 years (mean + SD: 33.4+8.1 years), with highly statistical significant difference between the two groups P value < 0.01.
When we compared both groups as regard history of blood transfusion, the difference was highly significant. In the group A, 56 (74.4%) were taken blood transfusion and 19 (25.3%) weren't. While in the group B there was 1 (10%) was taken blood transfusion and 9 (90%) weren't. This is presented in table (1) There is highly significant difference between both groups in Liver enzymes (P < 0.01) and there is significant difference in total bilirubin in group A than group B (P <0.01) Table (4). Table ( 2) and figure (1) showing IL10 level, in group A ranged from 5.8-28.6 with a mean 10.57, while in group B ranged from 3.3-8.2 with a mean 5.6, with highly statistical difference between the two groups (P < 0.01).
Of the 75 subjects investigated for HCV-RNA by RT-PCR in the group A, 8 (10.7%) were Positive (Occult HCV patient) and named group I, while 67 (89.3%) were negative and named group II, figure(2). As regard IL-10 level, in group I ranged from 6.8-28.6 with a mean 21.59, while in group B ranged from 5.8-13with a mean 9.26, with highly statistical difference between the two groups (P < 0.01), figure (3) 
DISCUSSION
Hepatitis C virus (HCV) is a commonly encountered pathogen in medical practice. It is estimated that 2-3% of the world is affected by HCV, with a prevalence of 170 million people (3% of the world's population) and incidence of 3-4 million per year.
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Patients on regular hemodialysis have higher infection rates for HCV than the general population 6 . There is suggestive evidence that T-cell immunoregulatory cytokines may play a key role in influencing the persistence of HCV infection and the extent of liver damage.
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IL10, produced mainly by macrophage, T-helper 2 (Th2) cells, and regulatory T cells, is a potent immunosuppressive cytokine as it inhibits the secretion of pro-inflammatory and antiviral cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) 11, 15 . In this study there were significant increase in serum level of IL-10 in hemodialysis patient than normal subjects (P <0.01), as shown in table 2 This finding could be explained that IL-10 is a potent inhibitor of proinflammatory mediators such as IL-1,tumor necrosis factor and IL-6 and it is a classical Th2 cytokine 14 . Regarding liver function tests There is highly statistically significant difference between group A and group B, in the levels of Liver enzymes (ALT&AST) (P < 0.01) and serum bilirubin (p < 0.03).
CONCLUSION
According to our study there were a statistical significant difference in level of IL10 in Occult HCV patient (Group I) than group II , and there is statistically significant difference as regard serum IL-10 protein level between HD patients with increased level of liver enzymes and healthy controls with normal liver and kidney functions
